,,trastuzumab deruxtecan
daiichi sankyo,daiichi sankyo,astrazeneca,astrazeneca
['destiny,breast,4', 'trastuzumab', 'breast', 'trastuzumab deruxtecan', 'destiny-breast04']
asco 2022 news: trastuzumab deruxtecan significantly improves the survival outcomes of previously treated patients with her2-low metastatic breast cancer relative to standard chemotherapy, show destiny-breast04 data.
Medicine Matters #oncology publishes the latest news, commentary, research, and educational resources in a range of topics across oncology.